martes, 22 de octubre de 2019

Competitor accuses 23andMe of 'false negatives' in cancer-gene testing

Competitor accuses 23andMe of 'false negatives' in cancer-gene testing

Cancer Briefing

Competitor accuses 23andMe of ‘false negatives’ in cancer-gene testing

By SHARON BEGLEY


GABE GINSBERG/GETTY IMAGES FOR LARAS
In a new study, Invitae concludes that in some ethnic groups the chance that 23andMe's tests will miss a cancer-causing DNA variant is 100%.

No hay comentarios: